The researcher’s effort to find the vaccine to treat the life threatening diseases HIV is waiting to open the door of final gate to enter the market. Clinical trials to test the efficiency and safety of the first HIV vaccines are under way. The HIV vaccine is formulated to target most virulent strain of the virus. It is most prevent virus in the countries like Sub Shara Africa and India, China and South America. The anti HIV shot contains trimeric HIV envelope protein (gp140) to fight against Clade C the virus responsible for causing virus in most of the patients. . The vaccine will be considered for further evaluation and testing if it found to be safe in the clinical trial. The vaccine is formulated to immune responsiveness following intramuscular injection. The clinical trial is on run with 36 HIV negative volunteer women aged between 18-45 years.
No comments:
Post a Comment